-
31.
公开(公告)号:US12202870B2
公开(公告)日:2025-01-21
申请号:US17455617
申请日:2021-11-18
Applicant: Hoffmann-La Roche Inc.
Inventor: Maria Amann , Peter Bruenker , Christina Claus , Claudia Ferrara Koller , Sandra Grau-Richards , Christian Klein , Viktor Levitski , Ekkehard Moessner , Pablo Umana
IPC: C07K14/525 , A61K38/00 , A61K39/395 , C07K14/705 , C07K16/28 , C07K16/30 , C07K16/40
Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) a polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by peptide linkers and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.
-
公开(公告)号:US20250017937A1
公开(公告)日:2025-01-16
申请号:US18779430
申请日:2024-07-22
Applicant: Hoffmann-La Roche Inc.
Inventor: Theresa M. BALLARD , Silvia Gatti MCARTHUR , Michael SAXE , Juergen WICHMANN , Thomas WOLTERING
IPC: A61K31/519 , A61K31/444
Abstract: This invention relates to a new medical use for certain chemical compounds and pharmaceutical compositions containing them. The invention relates to compounds which are mGlu2/3 negative allosteric modulators for use in the treatment of intellectual disabilities. In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of intellectual disabilities comprising a compound according to the invention and a pharmaceutically acceptable carrier.
-
公开(公告)号:US12186392B2
公开(公告)日:2025-01-07
申请号:US16679483
申请日:2019-11-11
Applicant: Ono Pharmaceutical Co., Ltd. , HOFFMANN-LA ROCHE INC.
Inventor: Christian Klein , Toshio Yoshizawa , Tomoko Yasuhiro
IPC: A61K39/395 , A61K31/522 , A61K39/40 , A61K45/06 , C07K16/28 , A61K39/00 , C07K16/00
Abstract: The present invention is directed to the combination therapy of an anti-CD20 antibody with a BTK inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with a type I anti-CD20 antibody or an afucosylated humanized B-Ly1 antibody and a BTK inhibitor.
-
公开(公告)号:US20250002452A1
公开(公告)日:2025-01-02
申请号:US18804965
申请日:2024-08-14
Applicant: ICAGEN, LLC , HOFFMANN-LA ROCHE INC.
Inventor: Mark CHAPMAN , Aaron GERLACH , Christopher John GRAHAM , Sylvain LEBRETON , David MOWREY , Anil NAIR , Roger David NORCROSS , Roger Lluis REDONDO PENA , Alena SAFAROVA , Martin SMRCINA , Luke James THOMPSON
IPC: C07C275/26 , A61K31/17 , A61K31/277 , A61K31/337 , A61K31/36 , C07C323/44 , C07D305/06 , C07D317/58
Abstract: The invention provides new bicyclopentanyl compounds having the general formula (I), or a solvate or a pharmaceutically acceptable salt thereof: wherein R1, R2, R3, R4, and R5 are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
-
公开(公告)号:US20240425855A1
公开(公告)日:2024-12-26
申请号:US18679965
申请日:2024-05-31
Applicant: Hoffmann-La Roche Inc.
Inventor: Simon AUSLAENDER , Ignazio GERACI
IPC: C12N15/113 , C12N15/10
Abstract: Herein is reported a composition comprising a pair of a first nucleic acid and a second nucleic acid, wherein the first nucleic acid comprises in the order a first part of a stem nucleic acid sequence, a cleavage site, a first stem loop nucleic acid sequences which 5′- and 3′-parts form a duplex, a first part of a catalytic core sequence, a second stem loop nucleic acid sequences which 5′- and 3′-parts form a duplex, a second part of the catalytic core sequence, and a second part of the stem nucleic acid sequence, which is complementary to the first part of the stem nucleic acid sequence and, thus, form a duplex therewith, wherein the second nucleic acid is complementary to at least a part of the first or the second part of the stem nucleic acid sequence, wherein binding of the second nucleic acid to the first nucleic acid results in a conformational change of the first nucleic acid, which is at least one of the dissociation of the first part of the first stem sequence from the second part of the stem sequence and the hybridization of one of the parts with the second nucleic acid, or the dissociation of loop I and loop II resulting in an inactivation of the catalytic activity, or the association of loop I and loop II resulting in an activation of the catalytic activity.
-
公开(公告)号:US20240424092A1
公开(公告)日:2024-12-26
申请号:US18754676
申请日:2024-06-26
Applicant: Genentech, Inc. , Hoffmann-La Roche Inc.
Inventor: Catherine LAI , Janet LAU , Anthony Jongha LEE , Shi LI , Yvonne Gail LIN-LIU , Christina Jeanne MATHENY , Diana MENDUS , Raymond D. MENG , Anh NGUYEN DUC , Jilpa Bhupendra PATEL , Thinh Quang PHAM , Isabelle Anne ROONEY , Heather Blythe STEVENS , Sarah Marie TROUTMAN , Lijia WANG , Yulei WANG , Patrick Georges Robert WILLIAMS , Benjamin WU , Yibing YAN , Aijing ZHANG , Xiaosong ZHANG , Marcus Dale BALLINGER , Hila BARAK , Elizabeth Alexandra BENNETT , Marcela Lucia CASTRO , Edward Namserk CHA , Hui Min Phyllis CHAN , Stephen CHUI , Christopher Roland COTTER , Viraj Vinay DEGAONKAR , Barbara Jennifer GITLITZ , Tien HOANG , Kimberly Mayumi KOMATSUBARA
IPC: A61K39/395 , A61K31/282 , A61K31/337 , A61K31/513 , A61K31/519 , A61K31/675 , A61K31/7048 , A61K31/7068 , A61K33/243 , A61K38/19 , A61K39/00 , A61K47/60 , A61K47/68 , A61P35/00 , A61P35/04 , C07K16/28
Abstract: The present invention relates to methods, uses, and compositions for the treatment of cancer (e.g., a lung cancer; a cervical cancer; a breast cancer; a head and neck cancer; a liver cancer; a bladder cancer; a gastric cancer; an esophageal cancer; a pancreatic cancer; a kidney or renal cancer; a melanoma; an ovarian cancer; or a colorectal cancer). More specifically, the invention concerns the treatment of patients having cancer with an anti-TIGIT antagonist antibody, including treatment with an anti-TIGIT antagonist antibody in a combination therapy.
-
公开(公告)号:US20240417387A1
公开(公告)日:2024-12-19
申请号:US18700259
申请日:2021-12-20
Applicant: Hoffmann-La Roche Inc.
Inventor: Kurt Amrein , Fabian Dey , Xiao Ding , Xinyi Huang , Christian Lerner , Houguang Shi , Xuefei Tan , Jun Wu , Jiamin Zheng , Mingwei Zhou
IPC: C07D401/14 , A61K31/4545 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/5377 , A61P31/04 , C07D413/14 , C07D487/10
Abstract: The present invention relates to compounds of formula (I), wherein R1 to R3, A, Q1, Q2, W and X are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
-
公开(公告)号:US20240412386A1
公开(公告)日:2024-12-12
申请号:US18702541
申请日:2022-10-20
Applicant: Hoffmann-La Roche Inc.
Inventor: Ralf Josef JAEGER , Xing CHEN
Abstract: Systems and computer-implemented methods for tracking movement of a subject comprise and perform the steps of: Obtaining depth image data of a subject's body during a predefined time period and tracking locations of a plurality of anatomical landmarks of the body based on the depth image data. In addition, a location of a predefined point is tracked in an environment, in which the subject is moving. The location of the one or more of the plurality of anatomical landmarks is adjusted relative to the location of the predefined point to obtain adjusted locations. A movement of the subject's body is determined based on the adjusted locations during the predefined time period.
-
公开(公告)号:US20240410900A1
公开(公告)日:2024-12-12
申请号:US18442986
申请日:2024-02-15
Applicant: Hoffmann-La Roche Inc.
Inventor: Christian KUENZEL , Achim LUTZ , Uwe WESSELS
IPC: G01N33/68 , C07K16/42 , G01N33/535 , G01N33/543 , G01N33/96
Abstract: The current invention is directed to an antibody comprising at least four binding sites specifically binding to an immunoglobulin Fc-region of the human IgG1 subclass comprising one, two, three or four amino acid changes compared to a wild-type Fc-region of the human IgG1 subclass for use as positive control and calibration standard in an immunoassay for the detection and quantification of anti-drug antibodies against said one, two, three or four amino acid changes in the Fc-region of the drug antibody.
-
公开(公告)号:US12162887B2
公开(公告)日:2024-12-10
申请号:US18059554
申请日:2022-11-29
Applicant: Hoffmann-La Roche Inc.
Inventor: Valerie Runtz-Schmitt , Patrick Schnider , Cosimo Dolente , Bernhard Fasching
IPC: C07D491/107 , C07D491/10 , C07D491/12 , C07D491/20 , C07D498/10 , C07D519/00
Abstract: The present invention provides spiro-oxazolones, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.
-
-
-
-
-
-
-
-
-